Ligand Pharmaceuticals LGND Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other accrued liabilities?
- Ligand Pharmaceuticals (LGND) reported other accrued liabilities of $300K in Q1 2026.
- What is the long-term trend for Ligand Pharmaceuticals's other accrued liabilities?
- Over 2 years (2022 to 2025), Ligand Pharmaceuticals's other accrued liabilities has grown at a -45.6% compound annual growth rate (CAGR), from $457K to $135K.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.